Core Insights - Biotechnology stocks and related ETFs experienced a significant rebound last year, indicating a strong recovery in the sector [1] - The trend has shown signs of cooling at the start of 2026, which may present new investment opportunities for some investors [1] Industry Summary - The biotechnology sector has demonstrated resilience with a notable bounce back in stock performance and ETF valuations [1] - Early 2026 has seen a moderation in this upward trend, suggesting potential volatility and shifts in investor sentiment [1]